Vitamin D has been studied in 2,177 papers since 1978: 678 trials and 510 observational studies in people, 83 in animals, 10 in cells, 846 reviews; 496 in the past year. Its furthest trials in people are at phase 3. The newest story, Nov 13, 2026: “Low vitamin D linked to greater frailty in adults”.
Independent labs report longer lifespan with cholecalciferol in mice and reduced senescence with calcitriol in human cells. Human trials report mortality reductions or no clear effect, with mixed telomere and physical-function results. Some trials across all uses remain unreported over a year after ending; some papers declare ties to developer Merck & Co., and a trial is company-sponsored.
2,136 findings in 985 papers from 1982 to 2026, 90 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 430 independent labs in 58 countries; 307 trials, 43 about aging, 120 with no results posted.
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
430 independent labs in 58 countries
360 findings against
307 trials, 43 about aging, 120 with no results posted
Studies of vitamin D measured 306 outcomes; the most studied are 25-hydroxyvitamin D (37 studies), physical function (13) and inflammation (13).
25-hydroxyvitamin D
↑upin humans37
37 studies
Cholecalciferol increases 25-hydroxyvitamin D in humans (Adults with prediabetes receiving supplementation plus lifestyle advice) (18.4 ± 4.5 to 27.6 ± 2.8 ng/mL).
“Serum 25(OH) D rose from 18.4 ± 4.5 to 27.6 ± 2.8 ng/mL ( P < 0.001).”
Human trialAdults with prediabetes receiving supplementation plus lifestyle adviceserum2000 IU once daily3 monthsn = 45
Cholecalciferol increases 25-hydroxyvitamin D in humans (73.0 vs 99.7 vs 120.4 nmol/L).
“After 12 months, the concentrations were 73.0 ± 17.8, 99.7 ± 21.1 and 120.4 ± 21.8 nmol/L in the placebo, 1600 IU/day and 3200 IU/day arms, respectively (P < 0.001).”
Cholecalciferol increases 25-hydroxyvitamin D in humans (T-scores -1.5 to -2.5) (38.2 ± 7.5 ng/mL vs 28.5 ± 6.8 ng/mL).
“Mean serum 25(OH)D levels were substantially higher (p = 0.003) in the liposomal group (38.2 ± 7.5 ng/mL) than those in the control cholecalciferol group (28.5 ± 6.8 ng/mL).”
Human trialT-scores -1.5 to -2.5liposomal800 IU/day + 1000 mg calcium24 monthsfemalesn = 153
Ergocalciferol improves physical function in humans.
“The vitamin D group demonstrated significant improvements in skeletal muscle mass, physical function, and quality of life scores compared to the control group”
Ergocalciferol improves physical function in humans.
“Administration of vitamin D2 supplementation resulted in significant improvements in overall physical performance, including better outcomes in the balance test (p = 0.01), gait speed (p = 0.009), chair stand test (p < 0.001), and SPPB score (p < 0.001).”
Ergocalciferol improves physical function in humans (p < 0.001).
“Significant improvements were observed in muscle mass (p = 0.04), balance test (p = 0.01), gait speed (p = 0.009), chair stand test (p < 0.001), short physical performance (p < 0.001)”
Cholecalciferol showed no clear effect on physical function in humans.
“There was no statistically significant interaction between treatment group and study time point for SPPB scores, grip strength, laying to standing systolic and diastolic blood pressure ratios, and ARR.”
Vitamin D decreases inflammation in humans (5000 IU daily compared with 1000 IU daily; IL-6 and TNF-α expression in PBMCs).
“After the intervention, supplementation with D5N and D5 significantly downregulated p16, interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) expression and decreased SA-β-gal activity compared to the D1 group.”
Human trial5000 IU daily compared with 1000 IU daily; IL-6 and TNF-α expression in PBMCsperipheral blood mononuclear cells5000 IU daily8 weeks
“Literature data reveal that vitamin D modulates gut microbiota diversity and composition, enhances immune resilience, and reduce systemic inflammation.”
Cholecalciferol improves cognitive function in humans (compared with placebo over 12 months).
“all intervention groups demonstrated significant improvements in cognitive function and reductions in five blood biomarkers (IL-1β, IL-18, NLRP3, Gasdermin D (GSDMD), cleaved caspase-1) compared to the placebo group (p < 0.05)”
Human trialcompared with placebo over 12 months800 IU/day12 months
Vitamin D is linked with better cognitive function in humans (overweight or obesity and metabolic syndrome) (β 1.18 × 10−2; 95% CI 0.19 × 10−2 to 2.17 × 10−2).
“energy-adjusted cumulative average dietary vitamin D intake as a continuous variable was associated with greater 2-year improvements in global cognitive function (β 1.18 × 10−2; 95% CI 0.19 × 10−2 to 2.17 × 10−2)”
Humansoverweight or obesity and metabolic syndrome2 yearsn = 5,454
Vitamin D is linked with better cognitive function in humans (3rd tertile vs 1st tertile of intake) (OR: 0.77, 95% CI: 0.57-0.98).
“individuals in the 3rd tertile of vitamin D intake (≥4.9 mcg/day) had significantly reduced odds of low performance on the CERAD test (OR: 0.77, 95% CI: 0.57-0.98; p = 0.031)”
Humans3rd tertile vs 1st tertile of intake≥4.9 mcg/day vs ≤2.4 mcg/day
Vitamin D improves cognitive function in humans (particularly for those who are deficient).
“Supplementation, particularly for those who are deficient, usually provides improvements resulting in moderate but meaningful improvement in mental health symptoms, neurodevelopmental outcomes, and cognitive function.”
Vitamin D showed no clear effect on mortality in humans (7.5% vs 10% at 6-month, 15% vs 12.5% at 1-year, 25% vs 27.5% at 2-year).
“Mortality rate 6-month after the surgery was 7.5% and 10% for the intervention and placebo groups, respectively (P value =.71), 15% and 12.5% at 1-year (P value =.83), and 25% and 27.5% at 2-year (P value =.98).”
Vitamin D showed no clear effect on mortality in patients with intertrochanteric fractures and a sufficient level of 25 (OH) VitD (7.5% vs 10% at 6 mo; 15% vs 12.5% at 1 yr; 25% vs 27.5% at 2 yr).
“Mortality rate 6-month after the surgery was 7.5% and 10% for the intervention and placebo groups respectively (P value = .71), 15% and 12.5% at 1-year (P value = .83), and 25% and 27.5% at 2-year (P value = .98).”
Human trialin patients with intertrochanteric fractures and a sufficient level of 25 (OH) VitDintramuscular ampule300,000 IUn = 80
Vitamin D decreases mortality in humans (threshold-dependent).
“reductions in cancer mortality, protection against autoimmune disorders, most convincingly multiple sclerosis, and decreased risk of acute respiratory infections, including COVID-19”
Vitamin D decreases mortality in silico (restricted to people with vitamin D insufficiency) (HR 0.85 [95% CI: 0.79-0.91]).
“major mortality reduction was expected in emulated trials that were restricted to people with vitamin insufficiency (HR 0.85 [95%CI: 0.79-0.91] and 0.81 [95%CI: 0.76-0.86])”
In silicorestricted to people with vitamin D insufficiency
Vitamin D showed no clear effect on mortality in silico (weighted to 25(OH)D distributions of original trials (vitamin D sufficient)) (HR 0.97 [95 % CI: 0.92-1.02]).
“Emulated trials with study populations weighted to the 25(OH)D distributions of the original trials yielded null results similar to those reported (hazard ratios [HR] 0.97 [95 % CI: 0.92-1.02]”
In silicoweighted to 25(OH)D distributions of original trials (vitamin D sufficient)5.3 years
Cholecalciferol showed no clear effect on handgrip strength in vitamin D-deficient hemodialysis patients with 25OHD ≤50 nmol/L (0.07 ± 3.40 kg (cholecalciferol) and -0.19 ± 3.35 kg (control), P = .682).
“HGS did not change significantly between randomization and end of the study in both groups”
Human trialin vitamin D-deficient hemodialysis patients with 25OHD ≤50 nmol/L100 000 IU monthly oral6 monthsn = 143
Cholecalciferol improves handgrip strength in humans.
“The WT group showed greater handgrip strength than the control group (p < 0.001), and the D group also showed improvement over the control group (p = 0.001).”
“It improved significantly at 6 and 12 months, similarly in men and women, and especially in prefrail and frail patients and patients with sarcopenia.”
Vitamin D improves handgrip strength in humans (decompensated cirrhosis and vitamin D deficiency or insufficiency) (p = 0.001 at 6 months, p = 0.002 at 12 months).
“handgrip strength improved at 6 (p = 0.001) and 12 (p = 0.002) months, similarly in women and men”
Human trialdecompensated cirrhosis and vitamin D deficiency or insufficiency6 to 12 months
“Both groups exhibited significant improvements in skeletal muscle mass, handgrip strength and glucose/lipid metabolism post-treatment, with the treatment group demonstrating superior enhancements (P<0.05).”
Human trialcombined with thermotherapy and resistance exercise, compared with thermotherapy and resistance exercise alone, in sarcopenia patientsn = 140
Vitamin D was not clearly linked with falls in humans (IRR 1.01, 95% CI 1.00-1.02, P = 0.237).
“no significant links were observed between vitamin D supplement usage and fall outcomes: all falls (Incident Rate Ratio [IRR] 1.01; 95 % CI 1.00-1.02; P = 0.237)”
Cholecalciferol showed no clear effect on falls in humans.
“mega-trials established that vitamin D supplementation with the equivalent of 2000 to 3300 IU/d of vitamin D3 had no favorable effect on risk of falls or fractures”
Vitamin D showed no clear effect on falls in humans (OR 1.01, 95% CI 0.92-1.11, p=0.86).
“vitamin D supplementation decreased the odds of having at least one fall by 1% (odds ratio [OR]=1.01; 95% confidence interval [CI], 0.92-1.11; p=0.86); however, the difference was not statistically significant”
The journals of gerontology. Series A, Biological sciences and medical sciences·
Vitamin D showed no clear effect on falls in humans (RR 1.03, 95% CI 0.98-1.09).
“intermittent or single high-dose vitamin D supplementation showed no significant beneficial effect in the prevention of either falls (RR, 1.03 [95% CI, 0.98-1.09]; I2 = 56.6%; n = 11)”
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Fasting blood glucose
↓downin humans7↔no changein humans1
8 studies
Cholecalciferol decreases fasting blood glucose in humans (112.6 ± 8.4 to 102.4 ± 7.3 mg/dL; greater improvement than controls, P < 0.001).
“The Vitamin D group demonstrated significant reductions in FBG (112.6 ± 8.4-102.4 ± 7.3 mg/dL)”
Human trialAdults with prediabetes; supplementation plus lifestyle advice compared with lifestyle advice alone2000 IU once daily3 monthsn = 90
Vitamin D decreases fasting blood glucose in humans.
“Our NMA of 21 RCTs suggested that, compared with control, LDS decreased fasting blood glucose (FBG) and was ranked as the most effective in decreasing FBG (surface under the cumulative ranking curve = 87.9%).”
Cholecalciferol decreases fasting blood glucose in humans (cosupplementation with flaxseed oil in elderly patients with T2DM) (MD: -22.83 mg/dL).
“reductions were observed in weight (MD: -1.73 kg, p < 0.001), BMI (MD: -0.67 kg/m2, p < 0.001), fasting blood glucose (MD: -22.83 mg/dL, p = 0.015)”
Human trialcosupplementation with flaxseed oil in elderly patients with T2DM50,000 IU every two weeks vitamin D3 + 500 mg TID flaxseed oil8 weeksn = 104
Cholecalciferol showed no clear effect on fasting blood glucose in humans (postmenopausal women with T2DM) (median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation, p = 0.059).
“fasting blood glucose values showed a median of 120 mg/dL at baseline and 110 mg/dL after cholecalciferol supplementation”
Human trialpostmenopausal women with T2DM1000 IU/day for 12 months, followed by 2000 IU/day for another 12 months24 monthsfemalesn = 34
Vitamin D decreases fasting blood glucose in humans (polycystic ovary syndrome) (MD -2.91 mg/dL, 95% CI (-4.78, -1.04) mg/dL).
“supplementation of vitamin D led to a notable reduction in the subsequent metabolic parameters: fasting blood glucose[MD=-2.91 mg/dL, 95% CI (-4.78, -1.04) mg/dL, P = 0.002]”
Vitamin D showed no clear effect on muscle strength in humans.
“Muscle strength gains (p < 0.001) as measured in seven exercises performed on RT equipment and increases (p < 0.001) in LBM were similar in the two groups.”
Human trialVitamin D-insufficient healthy men participating in resistance training; compared with placebo8000 IU daily12 weeksmalesn = 28
Vitamin D improves muscle strength in humans (menopause).
“Vitamin D demonstrates crucial importance for bone health and muscle strength in postmenopausal women, with a minimum dose of 800 IU/day required to achieve sufficient levels.”
International journal of Nutrition Pharmacology Neurological Diseases·
Vitamin D improves muscle strength.
“benefits of vitamin D on the muscular system are comparable to those of physical activity in terms of shaping the structural and functional changes in muscles”
Ergocalciferol showed no clear effect on grip strength in humans (between fixed-dose and severity-dependent groups) (P > .05).
“Muscle strength, gait speed, and serum insulin-like growth factor-1 level, as the mediators of muscle cell growth, were not different between the two groups at 6 months (P > .05).”
Human trialbetween fixed-dose and severity-dependent groups6 months
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·
Vitamin D is linked with better grip strength in humans.
“The study also showed that the grip strength and pinch strength of the patients in both groups increased after the intervention, and the difference between the two groups was statistically significant (p < 0.05).”
Vitamin D is linked with better grip strength in conjunction with lifestyle guidance and health education (p<0.05).
“the grip strength and pinch strength of the patients in both groups increased after the intervention, and the difference between the two groups was statistically significant (p<0.05).”
Humansin conjunction with lifestyle guidance and health educationoral
“Animal studies, primarily in mice, demonstrate vitamin D's positive effects on skeletal muscle function, such as improved grip strength and endurance.”
Cholecalciferol decreases C-reactive protein in humans (cosupplementation with flaxseed oil in elderly patients with T2DM) (MD: -0.98 μg/mL).
“The primary outcome, serum hs-CRP, was significantly reduced in the intervention group compared to controls (MD: -0.98 μg/mL, p = 0.034).”
Human trialcosupplementation with flaxseed oil in elderly patients with T2DM50,000 IU every two weeks vitamin D3 + 500 mg TID flaxseed oil8 weeksn = 104
Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina·
Cholecalciferol decreases C-reactive protein in humans (3.28 ± 2.02 versus 3.64 ± 2.42 mg/L).
“the hs-CRP levels were significantly lower (3.28 ± 2.02 VS 3.64 ± 2.42 mg/L).”
Human trialPregnant women with serum 25(OH)D <75 nmol/L; supplementation started at 24–28 weeks' gestation1600 IU/day versus 400 IU/day2 monthsfemalesn = 1,537
Vitamin D showed no clear effect on C-reactive protein in humans (Overweight or obesity, vitamin D deficiency, and no comorbidities) (MD 0.01; 95% CI -0.37 to 0.39).
“The VitD supplementation did not influence C-reactive protein”
ReviewOverweight or obesity, vitamin D deficiency, and no comorbiditiesDaily 1000–7000 international units or bolus 100,000–200,000 international units2 to 26 weeksn = 504
Vitamin D increases vitamin D in humans (vitamin D insufficiency) (p<0.05).
“After 12 weeks, the intervention group showed significant improvements in serum vitamin D levels and neuromuscular performance compared with placebo.”
Human trialvitamin D insufficiency60,000 IU weekly12 weeksn = 60
Vitamin D decreases HOMA-IR in humans (compared with low dosing strategy) (MD = −2.82; 95% CI, –5.06 to −0.57).
“And EHDS (MD = −2.82; 95% CI, –5.06 to −0.57) was more efficacious than LDS in reducing the homeostasis model assessment for insulin resistance (HOMA-IR) value.”
Vitamin D decreases HOMA-IR in humans (prediabetes) (MD = -2.82, 95% CI -5.06 to -0.57).
“And EHDS (MD = -2.82; 95% CI, -5.06 to -0.57) was more efficacious than LDS in reducing the homeostasis model assessment for insulin resistance (HOMA-IR) value.”
Human trialprediabetes≥4000 IU d-1 vs <1000 IU d-1
Cholecalciferol showed no clear effect on HOMA-IR in adult epilepsy patients treated with enzymatic antiseizure medications (–0.24 ± 3.71 vs. –0.14 ± 3.38).
“no significant differences were observed between groups regarding the changes in HOMA-IR (–0.24 ± 3.71 vs. –0.14 ± 3.38; p = 0.940)”
Human trialin adult epilepsy patients treated with enzymatic antiseizure medications2,000 IU/day12 weeks
“The BMI, WHR, insulin concentrations, homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) concentrations in women of Vitamin D group after 12 weeks of treatment were significantly lower than that in women of control group (P < 0.05).”
Human trialin women with PCOS2000 IU/day12 weeksfemalesn = 60
Vitamin D decreases HOMA-IR in male patients with schizophrenia and vitamin D deficiency (P = .014).
“The between-group comparison showed a significant difference in terms of PANSS-TS, GSK-3β, fasting serum insulin (FSI), and HOMA-IR (P = .022, P = .048, P = .013 and P = .014 respectively).”
Human trialin male patients with schizophrenia and vitamin D deficiencyserum2000 IU/day8 weeksmalesn = 48
Clinical and experimental hypertension (New York, N.Y. : 1993)·
All 306Fewer
What is vitamin D linked with?
133
Studies link vitamin D with 133 measures, among them mortality, type 2 diabetes and sarcopenia.
Mortality
↓downin humans8↑upin humans1RR 0.96
9 studies
Vitamin D lowers the risk of mortality in humans (fixed-effect model) (RR = 0.96 (95% CI [0.92, 1.00], p = 0.04)).
“Our meta‐analysis showed a statistically significant result regarding the benefit of vitamin D supplementation on all‐cause mortality with an RR = 0.96 (95% CI [0.92, 1.00], p = 0.04).”
Human trialfixed-effect model2 and 6.1 yearsn = 30,320
Vitamin D is linked with a lower risk of mortality in humans (stage 2 cardiovascular-kidney-metabolic syndrome, multimorbidity).
“sufficient serum 25-hydroxyvitamin D [25(OH)D] levels demonstrated a potential antagonistic effect on multimorbidity-related mortality, particularly for CVD”
Calcifediol is associated with mortality in humans (sarcopenia) (inflection point at 62.563 nmol/L).
“Our results indicated a significant non-linear association between 25(OH)D concentration and both all-cause mortality and cardiovascular (CVD) mortality.”
Calcifediol is linked with a lower risk of mortality in humans (compared with <30 nmol/L) (HR 0.69 (95% CI 0.57-0.84)).
“higher vitamin D levels (30 to < 50, 50 to < 75, and ≥75 nmol/L) were associated with a lower risk of all-cause mortality: HR (95% CI) of 0.82 (0.69-0.98), 0.74 (0.62-0.88), and 0.69 (0.57-0.84), respectively.”
Humanscompared with <30 nmol/Lserum≥75 nmol/L14.3 yearsn = 18,797
Calcifediol is linked with a lower risk of mortality in humans (serum 25(OH)D ≥75 nmol/L vs lowest group, fully adjusted model (Model 3)) (HR 0.48 (0.26, 0.87) vs lowest 25(OH)D group).
“those with serum 25(OH)D concentrations ≥75 nmol/L had hazard ratios (HRs) and 95% confidence intervals (CIs) of 0.48 (0.26, 0.87) for all-cause mortality”
Humansserum 25(OH)D ≥75 nmol/L vs lowest group, fully adjusted model (Model 3)≥75 nmol/Ln = 2,916
Calcifediol is linked with a lower risk of mortality in individuals with metabolic syndrome (HR 0.75 (0.64-0.89)).
“An "L-shaped" nonlinear dose-response correlation was detected between 25(OH)D and cancer/all-cause mortality; the respective HRs (95% CI) were 0.75 (0.64-0.89)”
Vitamin D is linked with a lower risk of mortality in humans.
“A negative dose-response relationship was observed between 25(OH)D concentration and cognition impairment at baseline, as well as the odds of all-cause mortality during follow-up.”
Humansmean (SD) follow-up of 3.8 (1.9) yearsn = 1,673
Revista Ibero-Americana de Humanidades, Ciências e Educação·
Type 2 diabetes
↓downin humans8↔no changein humans1HR 0.8–0.89
9 studies
Vitamin D lowers the risk of type 2 diabetes in humans.
“The EHDS was the top-ranked strategy in reducing FIN, HOMA-IR, HOMA of β-cell function, 2-h postload glucose, and new-onset T2D, and for improving normal glucose regulation.”
Calcifediol is associated with type 2 diabetes in humans (overall) (HR 0.80 (0.62-1.04)).
“the multivariable-adjusted hazard ratios (95% confidence intervals) for type 2 diabetes in those with vitamin D sufficiency were 0.80 (0.62-1.04) overall”
Vitamin D lowers the risk of type 2 diabetes in humans.
“vitamin D supplementation at doses sufficient to achieve 25-hydroxyvitamin D levels ≥ 40 ng/ml appears to confer additional benefit in reducing diabetes risk”
Reviewselected adults with prediabetes; supplementation sufficient to achieve 25-hydroxyvitamin D ≥40 ng/ml
The Journal of clinical endocrinology and metabolism·
Vitamin D lowers the risk of type 2 diabetes in humans (Vitamin D-replete populations with prediabetes).
“large trials show limited extra-skeletal benefits, apart from modest effects on cancer mortality and progression from prediabetes to Type 2 diabetes.”
ReviewVitamin D-replete populations with prediabetes
Vitamin D is associated with type 2 diabetes in humans.
“vitamin D contributes significantly to maintaining the metabolic balance of calcium and phosphorus and supporting bone health while potentially affecting the development and incidence of diabetes”
Calcifediol is linked with a lower risk of sarcopenia in humans (OR 0.47, 95% CI 0.23-0.94).
“Serum 25(OH)D concentrations were inversely associated with incident sarcopenia in men (odds ratio [OR] for the highest vs. lowest quartile, 0.47; 95% confidence interval [CI], 0.23-0.94; P for trend = 0.03)”
Calcifediol is linked with a lower risk of sarcopenia in humans (compared to participants with 25(OH)D levels < 50 nmol/L) (OR 0.61, 95% CI 0.48-0.77).
“0.61 (95% CI: 0.48, 0.77) for those with levels > 75 nmol/L”
Humanscompared to participants with 25(OH)D levels < 50 nmol/L> 75 nmol/L
The Journal of clinical endocrinology and metabolism·
Vitamin D lowers the risk of falls in humans (RR 0.85, 95% CI 0.74-0.95).
“Vitamin D supplementation at 800-1000 International Unit (IU)/d resulted in a lower risk of falls than placebo or no treatment (RR = 0.85, 95%CI: 0.74-0.95).”
Vitamin D is associated with cognitive function in humans (sleep disturbance and mild cognitive impairment) (adjusted mean diff 3.78 (SE 1.77), p = 0.039).
“Participants who took a daily dosage of 5000+ IU of vitamin D showed a marginally significant association with total MoCA score (adjusted mean (SE) = 3.78 (1.77); p = 0.039)”
Humanssleep disturbance and mild cognitive impairment5000+ IU dailyn = 54
Vitamin D is associated with cognitive function in humans (moderate positive correlation).
“Lower vitamin D levels were associated with reduced cognitive scores, weaker neuromuscular performance, altered calcium metabolism, and elevated inflammatory markers.”
Vitamin D is linked with a lower risk of cognitive impairment in humans (adjusted for confounding factors; robust to vitamin supplements and comorbidities) (OR 0.695 (95% CI 0.534-0.905), p = 0.003).
“serum Vitamin D (OR = 0.695, 95% CI: 0.534-0.905, p = 0.003) and FA (OR = 0.777, 95% CI: 0.604-0.999, p = 0.034) levels were inversely correlated with cognitive disorder risk”
Humansadjusted for confounding factors; robust to vitamin supplements and comorbiditiesn = 2,582
Vitamin D lowers the risk of bone fracture in vitamin D-deficient and older populations.
“Triangulated evidence provides strong and consistent support for a causal role of vitamin D in skeletal health, particularly in the prevention and treatment of rickets and osteomalacia, and in fracture risk reduction”
Reviewin vitamin D-deficient and older populations
Vitamin D lowers the risk of bone fracture in subgroup of RCTs with <1000 participants (RR 0.74, 95% CI 0.57-0.96).
“intermittent or single high-dose vitamin D supplementation reduced the risk of fractures in the subgroup meta-analysis of RCTs that included fewer than 1000 participants (RR, 0.74 [95% CI 0.57-0.96]”
Reviewin subgroup of RCTs with <1000 participantsintermittent or single high-dose
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·
Vitamin D is linked with a lower risk of frailty in humans (frailty phenotype) (OR 0.78, 95% CI 0.76–0.79, P < 0.001).
“Baseline vitamin D levels were found to be significantly associated with frailty status (frailty phenotype: ORfrail 0.78, 95% CI [0.76, 0.79], P < 0.001”
Vitamin D lowers the risk of frailty in humans (highest vs. lowest level of vitamin D in prospective cohort studies) (RR 0.71, 95% CI 0.60–0.84).
“Highest (vs. lowest) level of vitamin D in prospective cohort studies (with 14,153 participants and 2,137 cases with frailty) was significantly related to a 29% reduction in risk of frailty”
Reviewhighest vs. lowest level of vitamin D in prospective cohort studiesn = 14,153
The journals of gerontology. Series A, Biological sciences and medical sciences·
Benign paroxysmal positional vertigo
↓downin humans1
1 study
Vitamin D lowers the risk of benign paroxysmal positional vertigo in humans (idiopathic BPPV) (0.75 fewer clinical BPPV recurrences per one person year).
“Participants were analysed based on original group assignment with intention to treat protocol and vitamin D replacement in Group A was associated with 0.75 fewer clinical BPPV recurrences per one person year.”
Vitamin D lowers the risk of benign paroxysmal positional vertigo in humans with diet and Canalith Repositioning Procedure versus diet alone with CRP (-0.75 per person-year, P = 0.035).
“0.75 fewer clinical BPPV recurrences per one person year (P = 0.035) compared to Group B.”
Human trialwith diet and Canalith Repositioning Procedure versus diet alone with CRP12 month
Cholecalciferol lowers the risk of fragility fracture in humans (T-scores -1.5 to -2.5) (0.7%-2.0% vs 5.2%).
“Eight patients (5.2%) in the placebo group had fresh fragility fractures; two (1.3%), three (2.0%), and one (0.7%) in the conventional, micronized, and liposomal groups, respectively; χ2 = 7.42; p = 0.059.”
Vitamin D is associated with five-times sit-to-stand test in humans (at risk of sarcopenia, H-RT group) (rp = -0.55).
“In both groups, lower levels of vitamin B12 (H-RT: rp = -0.52; MT: rp = -0.50) and vitamin D (H-RT: rp = -0.55; MT: rp = -0.69) were associated with worse 5STS performance.”
Human trialat risk of sarcopenia, H-RT group32 weeksfemales
Cholecalciferol lowers the risk of coronary revascularization in humans.
“The same was true of coronary revascularisation, although the confidence interval for the hazard ratio included the null (0.89, 0.78 to 1.01;, supplementary figs 16 and 17).”
Independent labs report longer mouse lifespan and less senescence in human cells with vitamin D forms. Human trials report mixed telomere and mortality results and no clear effects on dementia or sarcopenia. Aging-related trials are registered; some trials across uses ended over a year ago without posted results, and some papers declare company ties.
Cholecalciferol extends worm lifespan and calcitriol reduces senescence in human cells in independently replicated studies; human trials disagree on telomere and frailty outcomes and show no clear effect on fractures. There are 39 aging-related registrations; across uses, 130 trials ended over a year ago without posted results. Human papers declare company ties, and Organon sponsors trials.
Independent labs report longer mouse lifespan with cholecalciferol and reduced human-cell senescence with calcitriol; human trials report unchanged or increased fractures and mixed frailty outcomes. Twenty registered trials concern aging; 131 trials across all uses ended over a year ago without posted results or citing papers. Some papers declare company ties, and Organon sponsors two trials.
Summary rewritten as its findings changed.
As it read before
Independent labs report lower human mortality and longer mouse lifespan with cholecalciferol; calcifediol associates with higher human mortality, and human trials report no reduction in nonvertebral fractures or improvement in physical function. Nine registered trials concern aging; 140 trials across uses ended over a year ago without posted results or citing papers. Some papers declare company ties, and Organon sponsors two trials.
Summary rewritten as its findings changed.
As it read before
Human studies associate vitamin D with lower mortality, independently replicated, but others report higher mortality; a trial reports slower leukocyte telomere attrition, while others report no fracture or physical-function benefit. Nine registered trials concern aging; across all uses, 140 ended over a year ago without posted results or citing papers. Authors include company employees, and papers declare developer and other company ties.
Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.Major cardiovascular events had a hazard ratio of 0.92 versus placebo, with 1 meaning no difference; heart attacks were less frequent.
Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.Low versus normal vitamin D was linked to a 76% higher relative risk of developing frailty in China and 27% in England.